Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
作者信息
Venditti J M, Baratta M C, Greenberg N H, Abbott B J, Kline I
出版信息
Cancer Chemother Rep. 1972 Aug;56(4):483-92.
PMID:5081591
Abstract
摘要
相似文献
1
Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.O-2,2'-环胞苷单乙酸酯（脱水阿糖胞苷；NSC-129220）的L1210抗白血病活性研究——关于治疗方案依赖性与阿糖胞苷（NSC-63878）的比较
Cancer Chemother Rep. 1972 Aug;56(4):483-92.
2
Influence of route of administration on antileukemic activity of cyclocytidine.给药途径对环胞苷抗白血病活性的影响。
Gan. 1972 Apr;63(2):279-80.
3
[Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].[用脱氧胞苷与致死剂量阿糖胞苷联合对白血病L1210进行选择性治疗]
Biull Eksp Biol Med. 1978 Mar;85(3):340-3.
4
Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
Cancer Chemother Rep. 1971 Dec;55(5):547-55.
5
6
Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
Cancer Chemother Rep. 1968 Apr;52(3):399-404.
7
Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Cancer Chemother Rep. 1972 Jun;56(3):327-34.
8
Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.在小鼠白血病模型中3-去氮尿苷对阿糖胞苷毒性的调节作用
Leuk Res. 1991;15(4):229-36. doi: 10.1016/0145-2126(91)90125-d.
9
10
引用本文的文献
1
Survival of L1210 leukemia cells and normal hematopoietic stem cells following in vivo administration of cyclocytidine.
Invest New Drugs. 1985;3(3):255-61. doi: 10.1007/BF00179429.
Zotero 插件